Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7321 to 7335 of 8223 results

  1. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued Reference number: GID-TA10836

    Technology appraisal guidance
    Discontinued

  2. Canakinumab with pembrolizumab and chemotherapy for untreated advanced non-small cell lung cancer with no EGFR or ALK mutations [ID3977]

    Discontinued Reference number: GID-TA10857

    Technology appraisal guidance
    Discontinued

  3. Tisagenlecleucel for treating relapsed or refractory aggressive diffuse large B-cell lymphoma after 1 systemic therapy [ID3974]

    Discontinued Reference number: GID-TA10859

    Technology appraisal guidance
    Discontinued

  4. Etrolizumab for previously treated moderately to severely active Crohn's disease [ID3965]

    Discontinued Reference number: GID-TA10870

    Technology appraisal guidance
    Discontinued

  5. Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558]

    Discontinued Reference number: GID-TA10875

    Technology appraisal guidance
    Discontinued

  6. Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]

    In development Reference number: GID-TA10882 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999]

    Discontinued Reference number: GID-TA10891

    Technology appraisal guidance
    Discontinued

  9. Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]

    Discontinued Reference number: GID-TA10892

    Technology appraisal guidance
    Discontinued

  10. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development Reference number: GID-TA10900 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development Reference number: GID-TA10905 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued Reference number: GID-TA10922

    Technology appraisal guidance
    Discontinued

  13. Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]

    Discontinued Reference number: GID-TA10927

    Technology appraisal guidance
    Discontinued

  14. Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]

    Discontinued Reference number: GID-TA10934

    Technology appraisal guidance
    Discontinued

  15. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development Reference number: GID-TA10935 Expected publication date: TBC

    Technology appraisal guidance
    In development